Antioxidant defence at the beginning of community-acquired pneumonia with lung infiltrative affection of different duration

T. Zhavoronok, E. Stepovaya, N. Ryazanceva, F. Tetenev, T. Ageeva, S. Mishustin (Tomsk, Russian Federation)

Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections
Session: Treatment and prevention of lower respiratory tract infections
Session type: Thematic Poster Session
Number: 2420
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Zhavoronok, E. Stepovaya, N. Ryazanceva, F. Tetenev, T. Ageeva, S. Mishustin (Tomsk, Russian Federation). Antioxidant defence at the beginning of community-acquired pneumonia with lung infiltrative affection of different duration. Eur Respir J 2009; 34: Suppl. 53, 2420

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Estimation of inflammatory process activity in community-acquired pneumonia
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010

Difference of immune response in patients with severe acute pneumonia and lung abscesses
Source: Eur Respir J 2004; 24: Suppl. 48, 189s
Year: 2004

Influence of antibiotic pre-treatment on inflammatory markers in community-acquired pneumonia
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008

The post-tuberculosis lung changes as risk factor of the community-acquired pneumonia delayed course
Source: Eur Respir J 2006; 28: Suppl. 50, 351s
Year: 2006

The tobacco-smoking influence on the community-acquired pneumonia course
Source: Eur Respir J 2006; 28: Suppl. 50, 247s
Year: 2006

Cardiovascular consequences of community-acquired pneumonia and other pulmonary infections
Source: Eur Respir Monogr 2020; 88: 212-228
Year: 2020


Effects of systemic steroids in patients with severe community-acquired pneumonia
Source: Eur Respir J 2007; 30: 951-956
Year: 2007



Inflammatory pattern in bacteriemic community-acquired pneumonia
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011


Adrenal function is related to prognosis in moderate community-acquired pneumonia
Source: Eur Respir J 2010; 36: 615-621
Year: 2010



Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia.
Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Year: 2019


Evolution of antimicrobial susceptibility of respiratory isolates in chronic obstructive pulmonary patients diagnosed of acquired community pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015

Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia
Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Year: 2007


Evaluation of incidental exacerbation of interstitial pneumonia in patients with non-respiratory diseases
Source: International Congress 2017 – Rare diseases
Year: 2017

Treatment of suppurative lung disease
Source: ISSN=1025-448x, ISBN=1-904097-33-2, page=168
Year: 2004

Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients
Source: International Congress 2015 – Immunodepression and severe pneumonia
Year: 2015


Effect of corticoids on the inflammatory response measured in blood in severe community-acquired pneumonia
Source: Eur Respir J 2003; 22: Suppl. 45, 461s
Year: 2003

The possibility to predict the danger of destabilization development of the ischemic heart disease course in patients with community-acquired pneumonia infected with chlamydophila pneumonia
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in chronic and acute airway diseases
Year: 2010

Prognostic impact of pre-existing interstitial lung disease in non-HIV patients with Pneumocystis pneumonia
Source: ERJ Open Res, 6 (2) 00306-2019; 10.1183/23120541.00306-2019
Year: 2020



Pulmonary tuberculosis in the differential diagnosis of community-acquired pneumonia
Source: Eur Respir J 2012; 40: 279
Year: 2012


Systemic cytokine levels in community-acquired pneumonia and their association with disease severity
Source: Eur Respir J 2002; 20: 990-995
Year: 2002